0570994 - ÚOCHB 2024 RIV NL eng J - Journal Article
Frejlachová, A. - Lencová, R. - Venhauerová, A. - Skaličková, M. - Uher, O. - Caisova, V. - Majer, Pavel - Tenora, Lukáš - Hansen, P. - Chmelař, J. - Kopecký, J. - Zhuang, Z. - Pacak, K. - Ženka, J.
The combination of immunotherapy and a glutamine metabolism inhibitor represents an effective therapeutic strategy for advanced and metastatic murine pancreatic adenocarcinoma.
International Immunopharmacology. Roč. 118, May (2023), č. článku 110150. ISSN 1567-5769. E-ISSN 1878-1705
Institutional support: RVO:61388963
Keywords : cancer * pancreatic adenocarcinoma * intratumoral * immunotherapy * glutamine antagonist
OECD category: Medicinal chemistry
Impact factor: 5.6, year: 2022
Method of publishing: Limited access
https://doi.org/10.1016/j.intimp.2023.110150
Permanent Link: https://hdl.handle.net/11104/0342323
Frejlachová, A. - Lencová, R. - Venhauerová, A. - Skaličková, M. - Uher, O. - Caisova, V. - Majer, Pavel - Tenora, Lukáš - Hansen, P. - Chmelař, J. - Kopecký, J. - Zhuang, Z. - Pacak, K. - Ženka, J.
The combination of immunotherapy and a glutamine metabolism inhibitor represents an effective therapeutic strategy for advanced and metastatic murine pancreatic adenocarcinoma.
International Immunopharmacology. Roč. 118, May (2023), č. článku 110150. ISSN 1567-5769. E-ISSN 1878-1705
Institutional support: RVO:61388963
Keywords : cancer * pancreatic adenocarcinoma * intratumoral * immunotherapy * glutamine antagonist
OECD category: Medicinal chemistry
Impact factor: 5.6, year: 2022
Method of publishing: Limited access
https://doi.org/10.1016/j.intimp.2023.110150
Permanent Link: https://hdl.handle.net/11104/0342323